-
2024-518835-13-00
5
Suspected Vascular Disease of supra-aortic (carotid/vertebrobasilar),
-
2024-518871-74-00
4
Locally Advanced or Metastatic Solid Tumours that harbour MET Amplific
-
2024-519246-75-01
4
Patients With Muscle-Invasive Bladder Cancer
-
2024-519298-21-00
5
Cancer-Associated Thrombosis (CAT).
-
2024-519402-12-00
5
uncomplicated appendicitis
-
2024-519624-24-00
4
HER3-mutant and HER2-not amplified metastatic breast cancer
-
2024-519655-28-00
5
Premenopausal patients with high-risk HR-positive/HER2-negative breast
-
2024-519786-22-01
9
metastatic non-small cell lung cancer (NSCLC)
-
2024-519818-31-01
5
Endometrial Cancer
Advanced, Recurrent, Metastatic, or Primary Unresec
-
2024-519894-20-01
5
Adult with an staphylococcal prosthetic joint infection treated with d
-
2024-520045-23-00
4
Kidney cancer
-
2024-520089-70-00
5
Cutaneous lupus erythematosus
-
2024-520125-36-00
3
Relapsed or Refractory Acute Myeloid Leukemia; Acute Myeloid Leukemia
-
2024-520320-28-00
11
supratentorial intracranial surgery with flap creation
-
2024-520414-21-00
5
Adult patients with a LVOS with large core within 9 hours of symptoms
-
2025-520565-51-00
5
small cell lung cancer
-
2025-520842-31-00
5
Population of study participants Pregnant women with PPROM at 22 to 33
-
2025-520976-25-00
4
Relapsed/refractory multiple myeloma
-
2025-521000-22-00
3
Patients with advanced malignancies
-
2025-521001-40-00
3
Advanced Malignancies and Hepatic Impairment
-
2025-521093-34-00
5
rare disease
-
2025-521113-13-00
10
Early Parkinson’s Disease
-
2025-521221-32-00
5
Advanced or Metastatic Non-Small Cell Lung Cancer
-
2025-521331-36-00
10
Patient with stabilized SSc-ILD (as defined by a decline of FVC ≤ 5%)